Comment on “Global burden of multiple myeloma in older adults from 1990 to 2021 and modelled projection to 2050” Authors: Fangfang Sun, Xiuli Sun Published: 2026 Dear Editor, Multiple myeloma (MM) is the second most prevalent hematological cancer, which is caused by an aberrant plasma cell lineage[1-3]. It starts as monoclonal gammopathy of unknown significance and can develop into extramedullary myeloma and plasma cell leukemia. The majority of MM patients are older individuals, with a median age of onset of 69 years. These older people often have underlying conditions associated with concomitant metabolic syndrome. Recently, Hu et al[4] used data from the Global Burden of Disease (GBD) 2021 to assess the prevalence and trends of MM in individuals 60 years of age and older. They discovered that the United States had the largest number of incidents, fatalities, and instances of disability-adjusted life years (DALYs). The most common instances were seen in China. In majority of the 21 GBD areas, there were significant regional and gender differences in the age-standardized incidence, age-standardized prevalence, age-standardized mortality, and age-standardized DALYs rates of MM in individuals 60 and older. Significant differences still exist between nations and regions despite the notable increases in DALYs, mortality, and morbidity among middle-aged and older men worldwide. Due to enhanced screening and an abundance of medical resources, MM patients often have greater survival rates in industrialized nations, whereas those in poor nations have higher mortality and lower survival rates. However, males from lower socioeconomic backgrounds experience a disproportionate burden of disease in industrialized countries, which is probably due to worse access to and quality of healthcare facilities. Therefore, in addition to focusing on high-risk male groups, global disease prevention and control initiatives should try to reduce health inequalities between regions, countries, and socioeconomic classes. Globally, middle-aged and older men may get more fair and effective health protection by enhancing international collaboration, allocating healthcare resources optimally, and developing screening and treatment technologies. Chromosome translocations affecting the immunoglobulin heavy chain are a major genetic event in the pathogenesis of MM. Gene expression is dysregulated as a result of certain chromosomal translocations. Moreover, the development of MM is also associated with other genetic alterations, including BRAF, NRAS, and KRAS. Genetic mutations are more likely to accumulate in older people due to the organism’s diminished ability to repair itself, which in turn causes the aberrant proliferation of plasma cells. The chance of having MM is further increased by the combination between genetic predisposition and other risk factors. There are several limitations to this study. First, inadequate registration, non-standardized diagnostic procedures, restricted access to healthcare, and a lack of complete original data may all have an impact on GBD estimations in low-income areas. These factors may result in underreporting and misclassification, thereby affecting the accuracy of disease burden projections and estimates. Second, genetic and epigenetic variables that might influence regional differences in MM incidence were not examined in the analysis. Lastly, clinical stratification for MM subtypes is not offered by the GBD framework. The work was conducted in compliance with the TITAN guideline[5].